TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04715204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Energy Oral Nutrition Supplement
Description: Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density \>0.9 kcal/mL. Formula with caloric density of \>1.2 kcal/mL is categorized as high energy ONS. This intervention has caloric density of 1.5 kcal/mL.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Energy Oral Nutrition Supplement
Description: Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density \>0.9 kcal/mL. This intervention has caloric density of 1 kcal/mL and it is categorized as standard energy ONS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formula-75/Formula-100
Description: Formula-75/Formula-100 is a special therapeutic foods to treat children with severe acute malnutrition. WHO designed F75 as a starter formula for stabilization phase with 75 kcal/100 mL, then it is continued with F100 for rehabilitation phase with 100 kcal/100 mL Formula-75 and Formula-100 are made according to recipe from WHO. The ingredients are skimmed milk powder, coconut oil, and sugar. Mineral mix is added, i.e. 2 ml every 100 ml of formula.~The composition of F-75:~Skimmed milk 25 g, coconut oil 100 g, sugar 30 g, mineral mix 20 ml, add water to 1000 ml~The composition of F-100:~Skimmed milk 80 g, coconut oil 50 g, sugar 60 g, mineral mix 20 ml, add water to 1000 ml
Study: NCT00845039

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 500 mg/m² every 14 days until disease progression or participant intolerance

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 500 mg/m² every 14 days until disease progression or participant intolerance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m² every 14 days until disease progression or participant intolerance
Study: NCT02078804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: 20 000 individuals will be randomised to a primary screening colonoscopy and 60 000 to take a feces test for occult blood (FIT) and if positive (10% of individuals) they will be offered a follow-up colonoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: 20 000 individuals will be randomised to a primary screening colonoscopy and 60 000 to take a feces test for occult blood (FIT) and if positive (10% of individuals) they will be offered a follow-up colonoscopy.
Study: NCT03032107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: -T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: -Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle
Study: NCT04279236

Intervention type: OTHER
Intervention: Abbreviated Profile Hearing Aid Benefit (APHAB)
Description: An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on 2 occasions.

Intervention type: OTHER
Intervention: Glasgow Benefit Inventory (GBI)
Description: An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on 2 occasions.

Intervention type: OTHER
Intervention: Additional follow-up visit
Description: There is an additional follow-up visit after surgery (compared to the routine clinical practice of the surgeons/clinics).
Study: NCT01365169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in walking and/or strengthening program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Use accelerometers, blood pressure monitor, heart rate monitor, GPS device, and smart phone
Study: NCT02246946

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Chest Physiotherapy
Description: To this group, routine physiotherapy exercises will be conducted plus Intermittent Positive Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: to this group, Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
Study: NCT03964740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile App intervention
Description: The intervention is based on the interventional group subjects use of a mobile device with an ad-hoc designed application (called ASMATIC). This app permit them (in a daily basis) to record asthma control variables (peak-flow and presence of core symptoms), have daily reminders on their medication for asthma control and decision support for patient disease self-management; and contains advice on healthy lifestyle habits, including personalized diet recommendations based on clinical criteria and associated recipes. The device also permits the study subject to communicate with the hospital and for the study team to review potential issues of interest on the patient's asthma control parameters which might need an intervention such us additional in-person consultations
Study: NCT00845039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m² every 14 days until disease progression or participant intolerance

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: IMC-A12 10 mg/kg every 14 days until disease progression or participant intolerance
Study: NCT05338567

Intervention type: DIAGNOSTIC_TEST
Intervention: Small intestine length measurement method
Description: Accuracy of digital 3D reconstruction for predicting small bowel length
Study: NCT01256242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augment Rotator Cuff
Description: rhPDGF-BB and bovine collagen matrix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Suture Repair
Description: standard suture repair
Study: NCT03166085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-H71
Description: PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1
Study: NCT04580459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE Parenting Group Treatment
Description: The CARE parenting group treatment is a 12-session, 60-minute group mentalizing-focused intervention with 3 monthly parent-child sessions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual (TAU)
Description: Treatment as usual (TAU) involves typical child outpatient mental health services, such as individual child appointments and medication management.
Study: NCT03802344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 cream
Description: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cal/BDP combination
Description: Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle cream
Study: NCT01863173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol
Description: using B blocker in patient group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo to control group
Study: NCT00798460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adefovir
Description: adefovir 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adefovir
Description: adefovir 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clevudine
Description: clevudine 30mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine
Description: lamivudine 100mg
Study: NCT03900104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles
Description: Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery. Injection performed with a trans-cervical catheter
Study: NCT01611545

Intervention type: GENETIC
Intervention: Pharmacogenomics
Description: Utilizing pharmacogenomics to determine the most effective treatment
Study: NCT01365169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Use accelerometers, blood pressure monitor, weight scale, and smart phone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Use smart phone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Use CO monitor and smart phone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Use Fitbit, weight scale and iPhone- or web-based app for self-reported data

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03900104

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical injection of technetium 99 m-labeled human albumin colloid particles
Description: Cervical injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery.
Study: NCT04005560

Intervention type: OTHER
Group type: OTHER
Intervention: no interventional study
Description: no interventional study
Study: NCT01365169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Use Fitbit and Actigraph
Study: NCT04140903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early transition to oral antibiotics
Description: Patients will be treated with an oral antibiotic regimen (e.g. amoxicillin + metronidazole) based upon pharmacokinetic and pharmacodynamic properties of the drugs, pathogen susceptibility, and any existing drug allergies or interactions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment of intravenous antibiotics
Description: Patients will continue standard intravenous antibiotic therapy for brain abscess (e.g. 3rd generation cephalosporin + metronidazole) according to international guidelines and pathogen susceptibility patterns.
Study: NCT04334317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-071 placebo-matching tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-071 placebo-matching tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-071 placebo-matching tablet.
Study: NCT02279381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: 4% chlorhexidine will be applied to the umbilical stump from day 1 to day 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: 4% chlorhexidine will be applied to the umbilical stump from day 1 to day 10

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care
Description: Skin to Skin Care which is Kangaroo mother care will be carried out by mother from Day 1 till the study completion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Essential Neonatal Care
Description: Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential Neonatal Care
Description: Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential Neonatal Care
Description: Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn
Study: NCT01415479

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative
Description: Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative
Description: Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default
Description: Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT). This is labeled the Default intervention since it attempts to shift the default choice from no screening to FIT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default
Description: Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT). This is labeled the Default intervention since it attempts to shift the default choice from no screening to FIT.
Study: NCT02839226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR/101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02305849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peficitinib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peficitinib
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral tablet/capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral tablet/capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral tablet/capsule
Study: NCT02882620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity (Group 1)
Description: The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medium Intensity (Group 2)
Description: The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reference Group (Group 3)
Description: The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
Study: NCT04068519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously
Study: NCT03062280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Modified release hydrocortisone
Study: NCT02957396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finerenone (BAY94-8862): 20 mg intact tablet
Description: 20 mg intact finerenone immediate-release tablet; single dose in the fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet
Description: 20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862): 20 mg suspension
Description: 20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
Study: NCT04309370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS modulates cortical activation depending on the stimulation parameters used. Physiological studies have provided evidence that suggests that high-frequency (HF) rTMS produces an increase in local cortical excitability. Studies have also demonstrated that rTMS may increase or decrease functional connectivity between separate but related cortical structures, utilizing high and low frequency stimulation, respectively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS modulates cortical activation depending on the stimulation parameters used. Physiological studies have provided evidence that suggests that high-frequency (HF) rTMS produces an increase in local cortical excitability. Studies have also demonstrated that rTMS may increase or decrease functional connectivity between separate but related cortical structures, utilizing high and low frequency stimulation, respectively.
Study: NCT02957396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862): 20 mg suspension
Description: 20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
Study: NCT05302076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity electrical current (LIEC)
Description: Each patient in the electrical group will be asked to wear a removable device containing a small electrical circuit that will supply the required electric current for five hours a day until the completion the retraction of the upper anterior teeth.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional fixed orthodontic appliance
Description: The maxillary arch will be levelled and aligned. The rectangular stainless steel archwires (0.019 × 0.025) with anterior 8mm height soldered hooks distal to the canines will be inserted. (250-300) g force will be applied on each side using two NiTi springs attached between the mini-implants and the soldered hooks in a direction approximately parallel to the occlusal plane for conducting an en-masse retraction.
Study: NCT02929420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiaoru Sanjie capsules
Description: Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.